Show
Sort by
-
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951
-
Prognostic significance of blasts with/without pleiocytosis in the cerebro-spinal fluid (CSF) of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) children leukemia group study 58881
-
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report
-
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951
-
Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations.
-
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial.
-
HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951
-
Treatment of childhood T-cell lymphoblastic non-Hodgkin lymphoma according to the strategy for acute lymphoblastic leukemia: Long-term results of the EORTC 58881 trial
-
Reversion of Autoimmune Lymphoproliferative Syndrome with an anti malaria drug: Clinical and molecular observations
-
Treatment outcome in infant acute lymphoblastic leukemia.
-
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial.
-
Long-term results of three randomized trials (58831,58832,58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report.
-
Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization.
-
Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma
-
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia
-
Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors
-
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors : results of the EORTC Children Leukemia Cooperative Study 58872
-
Juvenile myelomonocytic leukemia: Analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG)
-
Retroperitoneal teratoma as first sign of klinefelters-syndrome
-
TROPISETRON IN THE PREVENTION OF NAUSEA AND VOMITING IN 131 CHILDREN RECEIVING CYTOTOXIC CHEMOTHERAPY.
-
Control of nauseas and vomiting by Navoban(R) (tropisetron) in 131 children receiving cytotoxic chemotherapy.
-
Prevention of emesis by tropisetron (navoban) in children receiving cytotoxic therapy for solid malignancies
-
Bone metabolism and mineralization after cytotoxic chemotherapy including ifosfamide
-
Stress Echocardiography in the evaluation of late cardiac toxicity after moderate dose of anthracycline therapy in childhood
-
Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC-childhood Leukemia Cooperative Group.
-
Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy
-
Reversible cardiopathy after accidental overdose of mitoxantrone
-
Renal-function abnormalities after ifosfamide treatment in children
-
Type-III allergic reaction after infusion of immunoglobulins
-
CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m² methotrexate: a study from the EORTC Childrens' Leukemia Cooperative Group
-
Treatment of acute lymphoblastic leukemia in children with the BFM protocol: a cooperative pilot-study
-
Treatment of acute lymphoblastic leukemia in children with the BFM protocol: a cooperative study and analysis of prognostic factors
-
Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults